A Single Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3209590 in Japanese Patients With Type 2 Diabetes Mellitus
Latest Information Update: 08 Aug 2021
Price :
$35 *
At a glance
- Drugs Insulin efsitora alfa (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Eli Lilly and Company (India) Pvt. Ltd
- 29 Jun 2021 Results presented at the 81st Annual Scientific Sessions of the American Diabetes Association
- 02 Aug 2019 Status changed from active, no longer recruiting to completed.
- 15 Jul 2019 Status changed from recruiting to active, no longer recruiting.